Ophthalmological Abnormalities in Hereditary Ichthyosis (ICHTYO-KERATO)

Status Recruiting

Clinical Trial Summary

Presence/absence of subclinical keratoconus with corneal topographic abnormalities (skewed radial axes for forme fruste keratoconus, and inferior steepening for keratoconus suspect) on axial specular topography (TMS-4 Tomey), and elevation topographies: Pentacam (Oculus) and Orbscan (Bausch & Lomb).

Clinical Trial Description

Background: Hereditary ichthyosis are rare genetic diseases characterized by an abnormal epithelial keratinization due to mutations in gene involved in skin barrier. Patients present with scales on the whole body. Recent classification basically distinguishes syndromic from non-syndromic forms. Ichthyoses are severe diseases with significant impact on quality of life, due to troublesome symptoms (pruritus, pain), lack of effective therapy and complications such as ophthalmological anomalies. Among ophthalmological abnormalities, some are well known, such as eyelid abnormalities, including ectropion, and sicca syndrome. Conversely, corneal abnormalities such as keratoconus are not or very partially described in ichthyosis. The keratoconus is characterized by a corneal thickening and bulging with progressive loss of vision that may require a corneal transplantation. Its prevalence is 0.05% in its symptomatic presentation but may reach 10% when considering subclinical keratoconus diagnosed on basis of corneal topographies. These forme fruste keratoconus or keratoconus suspect may remain subclinical or instead progress to severe keratoconus. Corneal collagen crosslinking has been shown to strengthen the cornea in order to halt progressive keratoconus, justifying the need for early screening. Keratoconus is a complex condition of multifactorial etiology. With regards to the pathophysiology of the keratoconus, some hypotheses incriminate the corneal epithelial differentiation that is similar to the epidermal differentiation altered in ichthyosis. This link between both dermatological and ophthalmological abnormalities is supported by clinical experience. It's was observed that ichthyosis patients have frequently a subclinical keratoconus. In clinical practice, ophthalmological abnormalities are not commonly investigated in ichthyosis patients and there are no data on prevalence in the literature. Furthermore, there are no guidelines on screening or therapy of ophthalmological abnormities in ichthyosis.

The purpose of this project is to demonstrate that the prevalence of subclinical keratoconus (including forme fruste keratoconus and keratoconus suspect) is higher in ichthyosis compared to healthy controls.

Descriptive analysis of the studied population for primary outcome: The proportion of patients with subclinical keratoconus (including form fruste keratoconus and keratoconus suspect) will be described in each study-group and compared between study-groups using Mac Nemar Test. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03464994
Study type	Interventional
Source	University Hospital, Toulouse
Contact	Juliette MAZEREEUW, MD
Phone	05 67 77 81 41
Email	mazereeuw-hautier.j@chu-toulouse.fr
Status	Recruiting
Phase	N/A
Start date	July 18, 2017
Completion date	July 18, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03051347` - Asthma and Atopic Dermatitis Validation of PROMIS Pediatric Instruments	N/A
Completed	`NCT00004690` - Phase III Study of Monolaurin Cream Therapy for Patients With Congenital Ichthyosis	Phase 3
Completed	`NCT00074685` - National Registry for Ichthyosis and Related Disorders
Completed	`NCT03641261` - Therapeutic Education Using an Internet Application in Hereditary Ichthyosis	N/A
Completed	`NCT03796052` - Study Determining Safety and Efficacy of Avena Sativa (Oat) Skincare Products for Treating Skin Dryness and Itching in Cancer Patients	N/A
Recruiting	`NCT05954416` - FARD (RaDiCo Cohort) (RaDiCo-FARD)
Active, not recruiting	`NCT05295732` - The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis	Phase 3
Terminated	`NCT02655861` - A Multi-center, Prospective Evaluation of Infants and Children With Congenital Ichthyosis
Recruiting	`NCT03417856` - Defining the Skin and Blood Biomarkers of Ichthyosis
Terminated	`NCT04697056` - A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis	Phase 2
Recruiting	`NCT06330350` - Qualitative Study in Patients With Genodermatoses and Healthcare Professionals on Reproductive Counselling
Enrolling by invitation	`NCT06330324` - Reproductive Options in Inherited Skin Diseases
Completed	`NCT03041038` - The Efficacy and Safety of Secukinumab in Patients With Ichthyoses	Phase 2
Not yet recruiting	`NCT06362447` - Efficacy of Injectable Gentamicin in Hereditary Ichthyosis	Phase 2
Active, not recruiting	`NCT04549792` - An Open-Label and Long-Term Extension Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Patients With Ichthyoses	Early Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.